74:@0.093792:0.957873:0.109687:0.957873:0.109687:0.938882:0.093792:0.938882:0.007305:0.008591
3:@0.038824:0.310836:0.060302:0.310836:0.060302:0.263358:0.038824:0.263358:0.021478
CHAPTER 3:@0.117647:0.067219:0.190423:0.067219:0.190423:0.047140:0.117647:0.047140:0.009172:0.009650:0.008799:0.008861:0.007388:0.007906:0.009359:0.003320:0.008321
derrepresentation. Finally, intrapatient tumor heterogeneity assessment in seven patients :@0.117647:0.121273:0.857007:0.121273:0.857007:0.100900:0.117647:0.100900:0.011322:0.009039:0.007807:0.007442:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006551:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.003287:0.011391:0.005615:0.011687:0.009405:0.005387:0.005182:0.007989:0.004497:0.003287:0.005615:0.011391:0.006437:0.007898:0.008811:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.003287:0.006166:0.011413:0.017485:0.010843:0.007807:0.003287:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.003287:0.009291:0.007531:0.007875:0.009039:0.007533:0.007601:0.017488:0.009039:0.011391:0.006437:0.003287:0.005615:0.011756:0.003287:0.007875:0.009336:0.009633:0.009039:0.011756:0.003287:0.011365:0.008813:0.006437:0.005545:0.009039:0.011391:0.006437:0.007670:0.004109
with organoids derived from multiple tumor locations, revealed differential response to :@0.117647:0.141852:0.857132:0.141852:0.857132:0.121479:0.117647:0.121479:0.014723:0.005273:0.006620:0.011459:0.004565:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.004565:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.004565:0.006414:0.007442:0.010843:0.017645:0.004565:0.017280:0.011550:0.004908:0.006437:0.005271:0.011162:0.005182:0.009039:0.004565:0.006166:0.011413:0.017485:0.010843:0.007807:0.004565:0.005182:0.011276:0.009106:0.008813:0.006437:0.005545:0.010845:0.011619:0.007670:0.004497:0.004554:0.007442:0.009336:0.009635:0.009288:0.009405:0.005182:0.009108:0.011391:0.004565:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.004565:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007873:0.009039:0.004565:0.006211:0.011048:0.004109
at least one drug for all patients, indicating the importance to evaluate multiple tumor :@0.117647:0.162431:0.856954:0.162431:0.856954:0.142058:0.117647:0.142058:0.008811:0.006437:0.005570:0.005182:0.009291:0.009291:0.007510:0.006437:0.005570:0.010843:0.011598:0.009039:0.005570:0.011391:0.007964:0.011413:0.009861:0.005570:0.006024:0.010843:0.007807:0.005570:0.009405:0.005385:0.005250:0.005570:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.005570:0.005615:0.011596:0.011391:0.005547:0.009108:0.008811:0.006437:0.005615:0.011459:0.009861:0.005570:0.006620:0.011299:0.009039:0.005570:0.005615:0.017278:0.011505:0.010843:0.007967:0.006551:0.009085:0.011596:0.008994:0.009039:0.005570:0.006209:0.011048:0.005570:0.009336:0.009838:0.009405:0.004908:0.011596:0.008811:0.006209:0.009039:0.005570:0.017280:0.011550:0.004908:0.006437:0.005273:0.011162:0.005182:0.009039:0.005570:0.006163:0.011413:0.017485:0.010845:0.007807:0.004109
locations.:@0.117647:0.183009:0.198636:0.183009:0.198636:0.162636:0.117647:0.162636:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497
In a systematic approach, we showed that PDO drug response correlated with several :@0.117647:0.224167:0.857093:0.224167:0.857093:0.203794:0.117647:0.203794:0.006894:0.011756:0.006095:0.009291:0.006095:0.007761:0.009724:0.007510:0.006209:0.009039:0.017577:0.008811:0.006437:0.005547:0.008994:0.006095:0.008811:0.011048:0.011071:0.007442:0.011139:0.009291:0.008765:0.011459:0.004497:0.006095:0.014518:0.009039:0.006095:0.007556:0.011299:0.010866:0.014518:0.009108:0.011391:0.006095:0.006620:0.011391:0.008811:0.006437:0.006095:0.011664:0.016504:0.016412:0.006095:0.011391:0.007967:0.011413:0.009861:0.006095:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.006095:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006209:0.009108:0.011391:0.006095:0.014723:0.005271:0.006620:0.011459:0.006095:0.007873:0.009336:0.009633:0.009039:0.007898:0.009405:0.005250:0.004109
clinical response measures. This included histopathological assessment of tumor regres-:@0.117647:0.244745:0.852941:0.244745:0.852941:0.224373:0.117647:0.224373:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.004200:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004200:0.017485:0.009291:0.009291:0.007510:0.011413:0.007442:0.009039:0.007670:0.004497:0.004200:0.011470:0.011470:0.005615:0.007670:0.004200:0.005615:0.011596:0.008768:0.004905:0.011345:0.011322:0.009108:0.011391:0.004200:0.011459:0.005615:0.007510:0.006209:0.010820:0.011368:0.008811:0.006620:0.011299:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.004200:0.009291:0.007535:0.007873:0.009039:0.007533:0.007604:0.017483:0.009039:0.011393:0.006437:0.004200:0.010845:0.006209:0.004200:0.006163:0.011413:0.017485:0.010845:0.007807:0.004200:0.007442:0.009039:0.009861:0.007442:0.009039:0.007615:0.007533
sion according to a three-tier method (CRS) , which is recommended for assessment of :@0.117647:0.265324:0.857049:0.265324:0.857049:0.244951:0.117647:0.244951:0.007601:0.005547:0.010843:0.011756:0.003572:0.009291:0.008994:0.008994:0.010843:0.007442:0.011391:0.005615:0.011459:0.009861:0.003572:0.006209:0.011048:0.003570:0.009291:0.003572:0.006620:0.011459:0.007442:0.009108:0.009039:0.007533:0.006437:0.005547:0.009039:0.007807:0.003570:0.017485:0.009131:0.006620:0.011299:0.011276:0.011391:0.003572:0.006939:0.014678:0.013376:0.010112:0.006939:0.018244:0.004497:0.003572:0.014792:0.011459:0.005545:0.008765:0.011459:0.003572:0.005615:0.007670:0.003572:0.007442:0.009108:0.008994:0.010843:0.017645:0.017485:0.009039:0.011596:0.011322:0.009108:0.011391:0.003572:0.006024:0.010845:0.007807:0.003570:0.009291:0.007533:0.007875:0.009039:0.007533:0.007601:0.017485:0.009039:0.011391:0.006437:0.003572:0.010843:0.006209:0.004109
285:@0.484537:0.257708:0.502782:0.257708:0.502782:0.245831:0.484537:0.245831:0.006082:0.006082:0.006082
response to neoadjuvant therapy . Histopathological grading of tumor regression offers :@0.117647:0.285903:0.857007:0.285903:0.857007:0.265530:0.117647:0.265530:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.003378:0.006209:0.011048:0.003378:0.011596:0.009108:0.011139:0.009291:0.011048:0.004953:0.011345:0.009838:0.009085:0.011391:0.006437:0.003378:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.009724:0.018265:0.004497:0.003378:0.016481:0.005615:0.007510:0.006209:0.010820:0.011368:0.008811:0.006620:0.011299:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.003378:0.009861:0.007896:0.009291:0.011391:0.005615:0.011459:0.009861:0.003378:0.010843:0.006209:0.003378:0.006163:0.011413:0.017485:0.010843:0.007807:0.003378:0.007442:0.009039:0.009861:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.003378:0.010843:0.005969:0.005787:0.009039:0.007624:0.007670:0.004109
308:@0.389648:0.278287:0.407893:0.278287:0.407893:0.266409:0.389648:0.266409:0.006082:0.006082:0.006082
the advantage to study each tumor site separately, as opposed to patient-wide measures :@0.117647:0.306482:0.857061:0.306482:0.857061:0.286109:0.117647:0.286109:0.006620:0.011299:0.009039:0.004896:0.009291:0.011322:0.009838:0.009085:0.011391:0.006551:0.009199:0.009656:0.009039:0.004896:0.006209:0.011048:0.004896:0.007510:0.006163:0.011345:0.011322:0.009724:0.004896:0.009291:0.009291:0.008765:0.011459:0.004896:0.006163:0.011413:0.017485:0.010843:0.007807:0.004896:0.007601:0.005273:0.006209:0.009039:0.004896:0.007875:0.009131:0.011368:0.009085:0.007898:0.008811:0.006209:0.008948:0.005182:0.007989:0.004497:0.004896:0.009291:0.007670:0.004896:0.010820:0.011048:0.011502:0.010957:0.007875:0.009108:0.011391:0.004896:0.006209:0.011048:0.004896:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.014723:0.005549:0.011320:0.009039:0.004908:0.017485:0.009288:0.009291:0.007512:0.011413:0.007442:0.009039:0.007670:0.004109
of response such as CA-125, RECIST, and survival outcomes. Furthermore, it is a direct :@0.117647:0.327060:0.857153:0.327060:0.857153:0.306687:0.117647:0.306687:0.010843:0.006209:0.004611:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004611:0.007510:0.011345:0.008765:0.011459:0.004611:0.009291:0.007670:0.004611:0.014678:0.013605:0.007533:0.010432:0.010432:0.010432:0.004497:0.004600:0.013376:0.012098:0.014678:0.007259:0.009861:0.010957:0.004497:0.004611:0.009085:0.011596:0.011391:0.004611:0.007512:0.011413:0.008398:0.009838:0.005547:0.009838:0.009405:0.005250:0.004611:0.010820:0.011071:0.006209:0.008994:0.010843:0.017485:0.009039:0.007670:0.004497:0.004611:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.004611:0.005271:0.006437:0.004611:0.005615:0.007670:0.004611:0.009291:0.004611:0.011391:0.005615:0.007442:0.009108:0.009108:0.006437:0.004109
measure of chemotherapy response, whereas the survival outcomes may also be influ-:@0.117647:0.347639:0.852941:0.347639:0.852941:0.327266:0.117647:0.327266:0.017485:0.009291:0.009291:0.007510:0.011413:0.007442:0.009039:0.005752:0.010843:0.006209:0.005752:0.008765:0.011302:0.009039:0.017485:0.010820:0.006617:0.011299:0.009039:0.007898:0.008813:0.011092:0.009724:0.005752:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.008743:0.004497:0.005752:0.014792:0.011299:0.009039:0.007442:0.009288:0.009291:0.007670:0.005752:0.006620:0.011299:0.009039:0.005752:0.007510:0.011413:0.008400:0.009838:0.005547:0.009838:0.009405:0.005250:0.005752:0.010820:0.011071:0.006209:0.008994:0.010843:0.017485:0.009039:0.007670:0.005752:0.017577:0.008925:0.009724:0.005752:0.009405:0.005250:0.007875:0.011048:0.005752:0.011254:0.009039:0.005752:0.005615:0.011756:0.005638:0.005296:0.011482:0.007533
enced by completeness of surgery, co-morbidity and other known prognostic factors. :@0.117647:0.368218:0.857073:0.368218:0.857073:0.347845:0.117647:0.347845:0.009039:0.011596:0.008994:0.009108:0.011391:0.006574:0.010843:0.009724:0.006574:0.008994:0.010843:0.017280:0.011162:0.005182:0.009131:0.006209:0.009039:0.011596:0.009039:0.007533:0.007670:0.006574:0.010843:0.006209:0.006574:0.007510:0.011413:0.007624:0.009656:0.009039:0.008398:0.007992:0.004497:0.006574:0.008994:0.011048:0.007533:0.017483:0.010843:0.007715:0.010820:0.005547:0.011391:0.005273:0.006437:0.009724:0.006574:0.009085:0.011596:0.011391:0.006574:0.010820:0.006620:0.011299:0.009039:0.007807:0.006574:0.010706:0.011596:0.010866:0.014723:0.011756:0.006574:0.011071:0.007442:0.011048:0.009861:0.011596:0.010957:0.007510:0.006437:0.005547:0.008994:0.006574:0.006209:0.009291:0.009108:0.006209:0.010843:0.007624:0.007670:0.004497:0.004109
While Bohm :@0.117647:0.388796:0.231712:0.388796:0.231712:0.368423:0.117647:0.368423:0.020704:0.011459:0.005752:0.005182:0.009039:0.004702:0.013080:0.010934:0.011459:0.017645:0.004109
et al:@0.232324:0.388796:0.266541:0.388796:0.266541:0.368213:0.232324:0.368213:0.008081:0.006300:0.004816:0.009952:0.005068
.  previously reported that the prognostic significance of the CRS on :@0.266540:0.388796:0.856963:0.388796:0.856963:0.368423:0.266540:0.368423:0.004497:0.018244:0.004702:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.004702:0.007442:0.009131:0.011505:0.010843:0.007967:0.006209:0.009108:0.011391:0.004702:0.006620:0.011391:0.008813:0.006437:0.004702:0.006620:0.011302:0.009039:0.004702:0.011069:0.007442:0.011048:0.009861:0.011598:0.010955:0.007510:0.006437:0.005547:0.008994:0.004702:0.007601:0.005615:0.009861:0.011756:0.005615:0.005684:0.005615:0.009108:0.009085:0.011596:0.008994:0.009039:0.004702:0.010843:0.006209:0.004702:0.006620:0.011299:0.009039:0.004702:0.014678:0.013376:0.010112:0.004702:0.010843:0.011756:0.004109
285:@0.271037:0.381180:0.289282:0.381180:0.289282:0.369303:0.271037:0.369303:0.006082:0.006082:0.006082
omental tumor lesions was greater than on primary tumor sites, we applied it to all tu-:@0.117647:0.409375:0.852941:0.409375:0.852941:0.389002:0.117647:0.389002:0.010843:0.017485:0.009039:0.011391:0.006551:0.009405:0.005250:0.005282:0.006166:0.011413:0.017485:0.010843:0.007807:0.005282:0.005182:0.009039:0.007601:0.005547:0.010843:0.011619:0.007670:0.005284:0.014723:0.009291:0.007670:0.005284:0.009861:0.007442:0.009288:0.008811:0.006209:0.009039:0.007807:0.005284:0.006620:0.011391:0.009085:0.011756:0.005284:0.010843:0.011756:0.005282:0.011073:0.007807:0.005615:0.017574:0.009087:0.008398:0.009724:0.005284:0.006163:0.011413:0.017485:0.010843:0.007807:0.005284:0.007601:0.005273:0.006209:0.009039:0.007670:0.004497:0.005284:0.014518:0.009039:0.005284:0.008811:0.011048:0.011162:0.005250:0.005547:0.009106:0.011391:0.005284:0.005273:0.006437:0.005284:0.006209:0.011048:0.005282:0.009405:0.005387:0.005250:0.005284:0.006163:0.011411:0.007533
mor locations where organoids were derived from. In this study, we present a correlation :@0.117647:0.429954:0.856981:0.429954:0.856981:0.409581:0.117647:0.409581:0.017485:0.010843:0.007807:0.003766:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.003766:0.014789:0.011299:0.009039:0.007442:0.009039:0.003766:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.003766:0.014518:0.009039:0.007442:0.009039:0.003766:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.003766:0.006414:0.007442:0.010843:0.017645:0.004497:0.003766:0.006894:0.011756:0.003766:0.006620:0.011459:0.005615:0.007670:0.003766:0.007510:0.006163:0.011345:0.011322:0.007989:0.004497:0.003766:0.014518:0.009039:0.003766:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.003766:0.009291:0.003766:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.004109
between CRS and PDO drug response to carboplatin and paclitaxel combination treat-:@0.117647:0.450532:0.852941:0.450532:0.852941:0.430160:0.117647:0.430160:0.011254:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.004794:0.014678:0.013376:0.010112:0.004794:0.009085:0.011596:0.011391:0.004794:0.011664:0.016504:0.016412:0.004794:0.011391:0.007967:0.011413:0.009861:0.004794:0.007442:0.009039:0.007512:0.011502:0.010843:0.011619:0.007875:0.009039:0.004794:0.006209:0.011048:0.004794:0.009108:0.009085:0.007715:0.011254:0.010820:0.011162:0.005433:0.008811:0.006437:0.005615:0.011756:0.004794:0.009085:0.011596:0.011391:0.004794:0.011368:0.009291:0.008765:0.005250:0.005271:0.006551:0.009291:0.009884:0.008948:0.005250:0.004794:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.004794:0.006437:0.007442:0.009291:0.008811:0.006346:0.007533
ment.:@0.117647:0.471111:0.166496:0.471111:0.166496:0.450738:0.117647:0.450738:0.017485:0.009039:0.011391:0.006437:0.004497
In order to bring PDO-based drug response assessment to the clinic, PDO establishment :@0.117647:0.512269:0.856959:0.512269:0.856959:0.491896:0.117647:0.491896:0.006894:0.011756:0.003424:0.010843:0.007444:0.011322:0.009039:0.007807:0.003424:0.006209:0.011048:0.003424:0.010820:0.007807:0.005615:0.011459:0.009861:0.003424:0.011664:0.016501:0.016412:0.007533:0.011117:0.009291:0.007875:0.009108:0.011391:0.003424:0.011391:0.007967:0.011413:0.009861:0.003424:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.003424:0.009291:0.007533:0.007875:0.009039:0.007533:0.007601:0.017485:0.009039:0.011391:0.006437:0.003424:0.006209:0.011048:0.003424:0.006620:0.011299:0.009039:0.003424:0.008765:0.005250:0.005615:0.011756:0.005547:0.008994:0.004497:0.003424:0.011664:0.016501:0.016412:0.003424:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011459:0.017485:0.009039:0.011391:0.006437:0.004109
and drug screening needs to be performed within a short timeframe, preferably limited :@0.117647:0.532847:0.856931:0.532847:0.856931:0.512474:0.117647:0.512474:0.009085:0.011596:0.011391:0.004702:0.011391:0.007964:0.011413:0.009861:0.004702:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.004702:0.011598:0.009106:0.009108:0.011391:0.007670:0.004702:0.006211:0.011048:0.004702:0.011251:0.009039:0.004702:0.011505:0.009039:0.007807:0.006024:0.010843:0.007807:0.017488:0.009106:0.011391:0.004702:0.014723:0.005271:0.006620:0.011459:0.005615:0.011756:0.004702:0.009291:0.004702:0.007556:0.011299:0.010843:0.007967:0.006437:0.004702:0.006437:0.005615:0.017485:0.009039:0.006414:0.007898:0.009085:0.017485:0.008743:0.004497:0.004702:0.011071:0.007442:0.009039:0.006026:0.009039:0.007898:0.009108:0.010911:0.005182:0.009724:0.004702:0.005250:0.005615:0.017645:0.005273:0.006209:0.009108:0.011391:0.004109
to the diagnosis-treatment interval. In line with previous studies:@0.117647:0.553426:0.678408:0.553426:0.678408:0.533053:0.117647:0.533053:0.006209:0.011048:0.007145:0.006620:0.011299:0.009039:0.007145:0.011391:0.005798:0.009199:0.009861:0.011596:0.010957:0.007601:0.005615:0.007670:0.007533:0.006437:0.007442:0.009291:0.008811:0.006437:0.017483:0.009039:0.011393:0.006437:0.007145:0.005615:0.011391:0.006207:0.009039:0.008400:0.009838:0.009405:0.004976:0.004497:0.007145:0.006894:0.011756:0.007145:0.005250:0.005615:0.011596:0.009039:0.007145:0.014723:0.005273:0.006620:0.011459:0.007145:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007670:0.007145:0.007510:0.006163:0.011345:0.011391:0.005547:0.009039:0.007670
279,309–311:@0.678388:0.545810:0.742626:0.545810:0.742626:0.533933:0.678388:0.533933:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082:0.006880:0.006082:0.006082:0.006082
, we demon-:@0.742624:0.553426:0.852941:0.553426:0.852941:0.533053:0.742624:0.533053:0.004497:0.007145:0.014518:0.009039:0.007145:0.011322:0.009039:0.017485:0.010843:0.011751:0.007533
strated that PDO establishment and drug screening is feasible within three weeks. Other :@0.117647:0.574005:0.857089:0.574005:0.857089:0.553632:0.117647:0.553632:0.007510:0.006437:0.007898:0.008811:0.006209:0.009108:0.011391:0.003926:0.006620:0.011391:0.008811:0.006437:0.003926:0.011664:0.016501:0.016412:0.003926:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011459:0.017485:0.009039:0.011391:0.006437:0.003926:0.009085:0.011596:0.011391:0.003926:0.011391:0.007964:0.011413:0.009861:0.003926:0.007875:0.008994:0.007442:0.009106:0.009039:0.011756:0.005615:0.011459:0.009861:0.003926:0.005615:0.007670:0.003926:0.006026:0.009291:0.009291:0.007601:0.005547:0.010911:0.005182:0.009039:0.003926:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.003926:0.006620:0.011459:0.007442:0.009108:0.009039:0.003926:0.014518:0.009108:0.008948:0.010523:0.007670:0.004497:0.003926:0.016501:0.006620:0.011299:0.009039:0.007807:0.004109
studies showed a timeframe of one to two weeks. To further validate the predictive value :@0.117647:0.594583:0.857118:0.594583:0.857118:0.574210:0.117647:0.574210:0.007510:0.006163:0.011345:0.011391:0.005547:0.009039:0.007670:0.004086:0.007556:0.011299:0.010866:0.014518:0.009108:0.011391:0.004086:0.009291:0.004086:0.006437:0.005615:0.017485:0.009039:0.006414:0.007896:0.009087:0.017485:0.009039:0.004086:0.010843:0.006209:0.004086:0.010843:0.011596:0.009039:0.004086:0.006209:0.011048:0.004086:0.006437:0.014518:0.011048:0.004086:0.014518:0.009108:0.008948:0.010523:0.007670:0.004497:0.004086:0.010866:0.011048:0.004086:0.006369:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.004086:0.009838:0.009405:0.005250:0.005545:0.011573:0.008811:0.006209:0.009039:0.004086:0.006620:0.011299:0.009039:0.004086:0.011071:0.007442:0.009108:0.011391:0.005547:0.009108:0.006437:0.005547:0.009633:0.009039:0.004086:0.009838:0.009405:0.004908:0.011345:0.009039:0.004109
of PDOs, we plan to undertake a prospective trial in which organoids will be derived :@0.117647:0.615162:0.856979:0.615162:0.856979:0.594789:0.117647:0.594789:0.010843:0.006209:0.006163:0.011664:0.016504:0.016253:0.007670:0.004497:0.006163:0.014518:0.009039:0.006163:0.011160:0.005433:0.009087:0.011756:0.006163:0.006209:0.011048:0.006163:0.011413:0.011596:0.011322:0.009039:0.007967:0.006551:0.009405:0.010272:0.009039:0.006163:0.009291:0.006163:0.011071:0.007442:0.010957:0.007510:0.011505:0.009108:0.009108:0.006437:0.005547:0.009633:0.009039:0.006163:0.006437:0.007807:0.005798:0.009405:0.005250:0.006163:0.005615:0.011756:0.006163:0.014792:0.011459:0.005547:0.008765:0.011459:0.006163:0.010843:0.007624:0.009861:0.009085:0.011596:0.010845:0.005545:0.011391:0.007670:0.006163:0.014723:0.005750:0.005387:0.005250:0.006163:0.011251:0.009039:0.006163:0.011324:0.009039:0.007807:0.005545:0.009635:0.009106:0.011391:0.004109
from both primary and recurrent tumors and tested for response to drugs provided in :@0.117647:0.635741:0.857075:0.635741:0.857075:0.615368:0.117647:0.615368:0.006414:0.007442:0.010843:0.017645:0.005433:0.011254:0.010820:0.006620:0.011459:0.005433:0.011071:0.007807:0.005615:0.017577:0.009085:0.008400:0.009724:0.005433:0.009085:0.011596:0.011391:0.005433:0.007442:0.009106:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.005433:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.005433:0.009085:0.011596:0.011391:0.005433:0.006209:0.009039:0.007510:0.006211:0.009106:0.011391:0.005433:0.006026:0.010845:0.007807:0.005433:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.005433:0.006209:0.011048:0.005433:0.011391:0.007967:0.011413:0.009724:0.007670:0.005433:0.011071:0.007442:0.010866:0.009838:0.005547:0.011322:0.009108:0.011391:0.005433:0.005615:0.011756:0.004109
the clinic, while clinical response is systematically monitored.:@0.117647:0.656319:0.630857:0.656319:0.630857:0.635947:0.117647:0.635947:0.006620:0.011299:0.009039:0.004109:0.008765:0.005250:0.005615:0.011756:0.005547:0.008994:0.004497:0.004109:0.014789:0.011459:0.005752:0.005182:0.009039:0.004109:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.004109:0.007442:0.009039:0.007510:0.011502:0.010843:0.011621:0.007873:0.009039:0.004109:0.005615:0.007670:0.004109:0.007761:0.009724:0.007510:0.006209:0.009039:0.017577:0.008811:0.006437:0.005547:0.009108:0.009405:0.005387:0.005182:0.009724:0.004109:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007442:0.009108:0.011117:0.004497
Considering intrapatient drug response heterogeneity, derivation of organoids from :@0.117647:0.697477:0.857123:0.697477:0.857123:0.677104:0.117647:0.677104:0.014997:0.010843:0.011619:0.007601:0.005547:0.011322:0.009039:0.007807:0.005615:0.011459:0.009861:0.008309:0.005615:0.011391:0.006437:0.007898:0.008811:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.008309:0.011391:0.007967:0.011413:0.009861:0.008309:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.008309:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.007989:0.004497:0.008309:0.011322:0.009039:0.007807:0.005547:0.009838:0.008811:0.006437:0.005547:0.010843:0.011756:0.008309:0.010843:0.006209:0.008309:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005549:0.011391:0.007670:0.008309:0.006414:0.007442:0.010843:0.017645:0.004109
multiple tumor locations of individual patients, may further improve treatment alloca-:@0.117647:0.718056:0.852941:0.718056:0.852941:0.697683:0.117647:0.697683:0.017280:0.011550:0.004908:0.006437:0.005273:0.011162:0.005182:0.009039:0.005159:0.006163:0.011413:0.017485:0.010843:0.007807:0.005159:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.005159:0.010843:0.006209:0.005159:0.005615:0.011596:0.011391:0.005547:0.009838:0.005547:0.011048:0.011596:0.009402:0.005250:0.005159:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.005159:0.017577:0.008925:0.009724:0.005159:0.006369:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.005159:0.005615:0.017280:0.011071:0.007442:0.010866:0.009633:0.009039:0.005159:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.005159:0.009405:0.005387:0.005182:0.011276:0.009108:0.009245:0.007533
tion . Although sequencing studies have shown that OCs display extensive inter- and :@0.117647:0.738634:0.857072:0.738634:0.857072:0.718261:0.117647:0.718261:0.006437:0.005547:0.010843:0.011756:0.018245:0.004497:0.005262:0.015066:0.004908:0.006620:0.011299:0.010820:0.011413:0.009930:0.011459:0.005262:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.005262:0.007510:0.006163:0.011345:0.011391:0.005547:0.009039:0.007670:0.005262:0.011391:0.008925:0.009635:0.009039:0.005262:0.007556:0.011299:0.010866:0.014723:0.011756:0.005262:0.006620:0.011391:0.008811:0.006437:0.005262:0.016778:0.014678:0.007670:0.005262:0.011391:0.005615:0.007510:0.011162:0.005433:0.008925:0.009724:0.005262:0.009108:0.010089:0.006209:0.009039:0.011619:0.007601:0.005547:0.009633:0.009039:0.005273:0.005615:0.011391:0.006211:0.009039:0.007234:0.007533:0.005273:0.009085:0.011596:0.011391:0.004109
312:@0.152230:0.731018:0.170475:0.731018:0.170475:0.719141:0.152230:0.719141:0.006082:0.006082:0.006082
intratumor heterogeneity on a genetic level:@0.117647:0.759213:0.484818:0.759213:0.484818:0.738840:0.117647:0.738840:0.005615:0.011391:0.006437:0.007898:0.008811:0.006163:0.011413:0.017485:0.010843:0.007807:0.005547:0.011302:0.009128:0.006211:0.009039:0.007442:0.011048:0.009656:0.009039:0.011598:0.009039:0.005271:0.006437:0.009724:0.005547:0.010843:0.011756:0.005547:0.009291:0.005547:0.009656:0.009039:0.011598:0.009128:0.006437:0.005547:0.008994:0.005547:0.005182:0.009336:0.009633:0.008948:0.005250
78,283:@0.484797:0.751597:0.517828:0.751597:0.517828:0.739720:0.484797:0.739720:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
, we could only partially link inter- and :@0.517826:0.759213:0.857076:0.759213:0.857076:0.738840:0.517826:0.738840:0.004497:0.005547:0.014518:0.009039:0.005547:0.008994:0.010820:0.011548:0.005182:0.011391:0.005547:0.010843:0.011870:0.005182:0.009724:0.005547:0.011368:0.009085:0.007967:0.006437:0.005798:0.009405:0.005387:0.005182:0.009724:0.005547:0.005250:0.005615:0.011870:0.010523:0.005547:0.005615:0.011391:0.006209:0.009039:0.007236:0.007533:0.005547:0.009085:0.011596:0.011391:0.004109
intratumor heterogeneous drug responses to genetic heterogeneity. Additionally, some :@0.117647:0.779792:0.857073:0.779792:0.857073:0.759419:0.117647:0.759419:0.005615:0.011391:0.006437:0.007898:0.008811:0.006163:0.011413:0.017485:0.010843:0.007807:0.005615:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009108:0.010820:0.011413:0.007670:0.005615:0.011391:0.007964:0.011413:0.009861:0.005615:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.007670:0.005615:0.006209:0.011048:0.005615:0.009656:0.009039:0.011598:0.009128:0.006437:0.005547:0.008994:0.005615:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.007989:0.004497:0.005615:0.014335:0.011322:0.011391:0.005273:0.006437:0.005545:0.010845:0.011687:0.009405:0.005387:0.005182:0.007989:0.004497:0.005615:0.007875:0.010843:0.017485:0.009039:0.004109
of the CNAs that we identified in genes reported to be related to drug response by the :@0.117647:0.800370:0.857048:0.800370:0.857048:0.779998:0.117647:0.779998:0.010843:0.006209:0.005490:0.006620:0.011299:0.009039:0.005490:0.014678:0.015408:0.014586:0.007670:0.005490:0.006620:0.011391:0.008811:0.006437:0.005490:0.014518:0.009039:0.005490:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.011391:0.005488:0.005615:0.011756:0.005490:0.009656:0.009039:0.011598:0.009039:0.007670:0.005490:0.007442:0.009128:0.011505:0.010843:0.007967:0.006209:0.009108:0.011391:0.005490:0.006209:0.011048:0.005490:0.011254:0.009039:0.005490:0.007442:0.008948:0.005433:0.008811:0.006209:0.009108:0.011391:0.005490:0.006209:0.011048:0.005490:0.011391:0.007964:0.011413:0.009861:0.005490:0.007442:0.009039:0.007512:0.011502:0.010843:0.011619:0.007875:0.009039:0.005490:0.010843:0.009724:0.005490:0.006620:0.011299:0.009039:0.004109
DGIdb might be non-contributive passenger events, given the high frequency of CNAs :@0.117647:0.820949:0.857141:0.820949:0.857141:0.800576:0.117647:0.800576:0.016504:0.015682:0.006620:0.011322:0.011025:0.004679:0.017645:0.005615:0.009930:0.011094:0.006437:0.004679:0.011254:0.009039:0.004679:0.011596:0.010843:0.011756:0.007533:0.008994:0.010843:0.011391:0.006437:0.007807:0.005547:0.010797:0.011071:0.006437:0.005547:0.009633:0.009039:0.004679:0.011368:0.009291:0.007533:0.007875:0.009039:0.011459:0.009656:0.009039:0.007807:0.004679:0.009336:0.009633:0.009039:0.011391:0.006437:0.007670:0.004497:0.004679:0.009861:0.005547:0.009633:0.009039:0.011756:0.004679:0.006620:0.011299:0.009039:0.004679:0.011459:0.005615:0.009927:0.011459:0.004679:0.006414:0.007442:0.009108:0.010706:0.011345:0.009039:0.011596:0.009382:0.009724:0.004679:0.010843:0.006209:0.004679:0.014678:0.015408:0.014586:0.007670:0.004109
in high-grade serous OC. Therefore, follow-up studies with increased sample sizes and :@0.117647:0.841528:0.856956:0.841528:0.856956:0.821155:0.117647:0.821155:0.005615:0.011756:0.005227:0.011459:0.005615:0.009927:0.011459:0.007533:0.009861:0.007898:0.009291:0.011322:0.009039:0.005227:0.007875:0.009039:0.007442:0.010820:0.011413:0.007670:0.005227:0.016778:0.014678:0.004497:0.005227:0.011470:0.011311:0.009039:0.007442:0.009039:0.006026:0.010843:0.007442:0.008743:0.004497:0.005227:0.006026:0.010934:0.005387:0.005182:0.010866:0.014723:0.007533:0.011069:0.011276:0.005227:0.007510:0.006163:0.011345:0.011391:0.005547:0.009039:0.007670:0.005227:0.014723:0.005273:0.006620:0.011459:0.005227:0.005615:0.011596:0.008994:0.007442:0.009291:0.009291:0.007875:0.009108:0.011391:0.005227:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.005227:0.007601:0.005615:0.008834:0.009039:0.007670:0.005227:0.009085:0.011596:0.011391:0.004109
deeper sequencing are required to decipher drug response associations with the candi-:@0.117647:0.862107:0.852941:0.862107:0.852941:0.841734:0.117647:0.841734:0.011322:0.009108:0.009131:0.011505:0.009039:0.007807:0.005113:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.005113:0.009085:0.007442:0.009039:0.005113:0.007442:0.009106:0.010706:0.011413:0.005615:0.007442:0.009108:0.011391:0.005113:0.006209:0.011048:0.005113:0.011322:0.009108:0.008994:0.005271:0.011165:0.011299:0.009039:0.007807:0.005113:0.011391:0.007967:0.011413:0.009861:0.005113:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.005113:0.009291:0.007533:0.007875:0.011276:0.008994:0.005798:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.005113:0.014723:0.005273:0.006620:0.011459:0.005113:0.006620:0.011299:0.009039:0.005113:0.009108:0.009085:0.011598:0.011391:0.005545:0.007533
date genes identified here, and to discover novel resistance mechanisms. Importantly :@0.117647:0.882685:0.856961:0.882685:0.856961:0.862312:0.117647:0.862312:0.011573:0.008811:0.006209:0.009039:0.006757:0.009656:0.009039:0.011596:0.009039:0.007670:0.006757:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.011391:0.006757:0.011299:0.009039:0.007442:0.008743:0.004497:0.006757:0.009085:0.011596:0.011391:0.006757:0.006209:0.011048:0.006757:0.011391:0.005615:0.007873:0.008994:0.010866:0.009633:0.009039:0.007807:0.006757:0.011596:0.010866:0.009633:0.008948:0.005250:0.006757:0.007442:0.009039:0.007601:0.005615:0.007510:0.006551:0.009085:0.011598:0.008994:0.009039:0.006757:0.017485:0.009108:0.008765:0.011391:0.009085:0.011756:0.005615:0.007601:0.017508:0.007670:0.004497:0.006757:0.006894:0.017280:0.011505:0.010843:0.007967:0.006551:0.009085:0.011391:0.006620:0.005182:0.009724:0.004109
however, the lack of complete correlation between genetic and functional testing at this :@0.117647:0.903264:0.857004:0.903264:0.857004:0.882891:0.117647:0.882891:0.011299:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.004748:0.006620:0.011299:0.009039:0.004748:0.005433:0.009291:0.008765:0.010523:0.004748:0.010843:0.006209:0.004748:0.008994:0.010843:0.017280:0.011165:0.005182:0.009131:0.006207:0.009039:0.004748:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.004748:0.011251:0.009131:0.006437:0.014520:0.009106:0.009039:0.011756:0.004748:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.004748:0.009085:0.011596:0.011391:0.004748:0.006369:0.011413:0.011596:0.009108:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.004748:0.006209:0.009039:0.007510:0.006437:0.005615:0.011459:0.009861:0.004748:0.008811:0.006437:0.004748:0.006620:0.011459:0.005615:0.007670:0.004109